Livongo (NASDAQ:LVGO) Reports Fourth Quarter and Full Year Financial Results
Revenue: $50.4 million (up 137% year-over-year) vs analyst expectations of $48.9 million
Adj EPS: -$0.06 vs analyst expectations of -$0.05
Full Year 2019 in Review
Revenue: Total revenue for the year was $170.2 million, up 149% year-over-year, and exceeding guidance range of $168.5 million to $169.0 million.
Livongo for Diabetes Members: 222,700 Members as of December 31, 2019, up 96% year-over-year.
Livongo Clients: 804 Clients as of December 31, 2019, up 95% year-over-year.
Customers: 30% of Fortune 500 companies vs 20% last year
Estimated Value of Agreements (EVA): $76.7 million, up from $56.1 million in the fourth quarter of 2018. It consists of the estimated value of agreements signed in the quarter with new Clients or expansions entered into with existing Clients.
Revenue: $60 million - $62 million vs analyst expectations of $57 million
Full Year 2020 Guidance
Revenue: $280 million-$290 million (revenue to grow between 65% and 71%) vs analyst expectations of $277.5 million
Did You Know... LVGO is on our list, and there are 19 more...
Each company in our 'Top Picks’ has been selected as a future crown jewel of technology. Market correction or not, recession or not, the growth in these areas is a near certainty.
The precious few thematic top picks, research dossiers, and alerts are available for a limited time at a 30% discount.